- Home
- YQ vs RDHL Comparison
YQ vs RDHL Comparison
Compare YQ & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- RDHL
- Stock Information
- Founded
- YQ 2012
- RDHL 2009
- Country
- YQ China
- RDHL Israel
- Employees
- YQ N/A
- RDHL N/A
- Industry
- YQ Other Consumer Services
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- YQ Real Estate
- RDHL Health Care
- Exchange
- YQ Nasdaq
- RDHL Nasdaq
- Market Cap
- YQ 19.4M
- RDHL 3.9M
- IPO Year
- YQ 2020
- RDHL N/A
- Fundamental
- Price
- YQ $3.09
- RDHL $1.52
- Analyst Decision
- YQ
- RDHL
- Analyst Count
- YQ 0
- RDHL 0
- Target Price
- YQ N/A
- RDHL N/A
- AVG Volume (30 Days)
- YQ 23.3K
- RDHL 43.0K
- Earning Date
- YQ 09-03-2025
- RDHL 09-05-2025
- Dividend Yield
- YQ N/A
- RDHL N/A
- EPS Growth
- YQ N/A
- RDHL N/A
- EPS
- YQ N/A
- RDHL N/A
- Revenue
- YQ $20,003,071.00
- RDHL $9,550,000.00
- Revenue This Year
- YQ N/A
- RDHL $381.91
- Revenue Next Year
- YQ N/A
- RDHL N/A
- P/E Ratio
- YQ N/A
- RDHL N/A
- Revenue Growth
- YQ N/A
- RDHL 157.62
- 52 Week Low
- YQ $1.26
- RDHL $1.06
- 52 Week High
- YQ $3.29
- RDHL $11.70
- Technical
- Relative Strength Index (RSI)
- YQ 78.73
- RDHL 52.49
- Support Level
- YQ $2.10
- RDHL N/A
- Resistance Level
- YQ $2.81
- RDHL $1.60
- Average True Range (ATR)
- YQ 0.20
- RDHL 0.07
- MACD
- YQ 0.10
- RDHL -0.02
- Stochastic Oscillator
- YQ 85.56
- RDHL 95.00
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.